Mylan’s Acquisition of Global Marketing Rights to Once-Monthly Glatiramer Acetate Product through an Investment in and Partnership with Mapi Pharma

Cravath is representing Mylan in connection with the transaction.

Mylan N.V. (“Mylan”), a global pharmaceutical company, and Mapi Pharma Ltd. (“Mapi Pharma”), a fully integrated, clinical late stage biopharmaceutical company, announced that they will partner on the development and commercialization of GA Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis. Mylan is acquiring global marketing rights to the product.

The Cravath team is led by partners Aaron M. Gruber (Picture) and Mark I. Greene and includes associate Alex L. Winkelman on M&A matters; partner David J. Kappos and associate Sean M. Gholz on intellectual property matters; and partner Kara L. Mungovan and associate Damien J. Rose on tax matters.

Involved fees earner: Aaron Gruber – Cravath Swaine & Moore; Mark Greene – Cravath Swaine & Moore; Alex Winkelman – Cravath Swaine & Moore; David Kappos – Cravath Swaine & Moore; Sean Gholz – Cravath Swaine & Moore; Kara Mungovan – Cravath Swaine & Moore; Damien Rose – Cravath Swaine & Moore;

Law Firms: Cravath Swaine & Moore;

Clients: Mylan, Inc.;


Author: Ambrogio Visconti